Cabometyx (cabozantinib) — Medica
Differentiated thyroid carcinoma
Initial criteria
- age ≥ 12 years
- differentiated thyroid carcinoma (papillary, follicular, or oncocytic)
- refractory to radioactive iodine therapy
- has tried lenvatinib or sorafenib
Approval duration
1 year